GlaxoSmithKline announced that the Food and Drug Administration (FDA) has approved Arnuity Ellipta (fluticasone furoate inhalation powder) for the maintenance treatment of asthma as prophylactic therapy in patients ≥12 years old.

Fluticasone furoate inhalation powder is an inhaled corticosteroid administered once-daily with the dry powder inhaler, Ellipta. The Ellipta inhaler is used with other FDA-approved respiratory medicines by GlaxoSmithKline. Fluticasone furoate is a synthetic trifluorinated corticosteroid that demonstrates anti-inflammatory activity.

RELATED: Once-Daily Fluticasone Furoate May Be Effective for Persistent Asthma

The FDA approval was based on efficacy and safety data of Arnuity Ellipta studied in over 3,600 patients with asthma.

Arnuity Ellipta will be available in 100mcg and 200mcg strengths.

For more information visit